Quoting Hagop Kantarjian on Twitter, “MD Anderson Cancer Center’s Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML.”
For article: Click here
Source: Hagop Kantarjian/Twitter